Latest J&JPRD Stories
RARITAN, N.J., Oct. 4 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S.
RARITAN, N.J., July 19 /PRNewswire/ -- A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release (ER) tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release (CR) tablets. The study found tapentadol ER was associated with a lower overall incidence of gastrointestinal adverse events than oxycodone CR (tapentadol ER, 52.0 percent; oxycodone CR, 64.1 percent) in patients with...
ORLANDO, Fla., June 26 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
BALTIMORE, May 7 /PRNewswire/ -- A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTAÂ® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.
RARITAN, N.J., May 3 /PRNewswire/ -- Data on tapentadol for the relief of acute and chronic pain, as well as patient and prescriber perceptions of oxycodone immediate-release treatments, will be presented at the 29th Annual Scientific Meeting of the American Pain Society (APS) May 6-8, 2010. Four of the 12 poster presentations will review analyses of tapentadol data, including a post-hoc analysis of a Phase 3 tolerability study on NUCYNTAÂ® (tapentadol) tablets for acute pain in elderly...
RARITAN, N.J., April 13 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) announced that the U.S.
SAN ANTONIO, Feb.
RARITAN, N.J., Dec. 30 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for ceftobiprole.
RARITAN, N.J., Dec. 1 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S.
- A handkerchief.
- Specifically— The legendary sweat-cloth; the handkerchief of St. Veronica, according to tradition miraculously impressed with the mask of Christ; also, the napkin about Christ's head (Johu xx. 7).
- In general, any miraculous portrait of Christ.